D.T. Le et al., in two subsequent studies, showed how immune checkpoint blockade with pembrolizumab induced an objective radiographic response in 40–53% patients with MMR-deficient cancers originated from various organs, in contrast to MMR-proficient malignancies, which did not benefit from the therapy [4,101]. This evidence concerns the gene MRC1 and cancer.